Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
The Multiple Myeloma Research Foundation Recognizes the Accomplishments of Dr. Margaret Hamburg, U.S. FDA Commissioner
The Multiple Myeloma Research Foundation Recognizes the Accomplishments of Dr. Margaret Hamburg, U.S. FDA Commissioner
Following the disclosure of Dr. Margaret Hamburg’s decision to complete her term as Commissioner of the U.S. Food and Drug Administration (FDA), the Multiple Myeloma Research Foundation (MMRF) issued the following statement to recognize the FDA’s significant accomplishments, and Dr. Hamburg’s outstanding partnership on behalf of patients, during her tenure.
Norwalk, Conn., Feb. 6, 2014 – Following the disclosure of Dr. Margaret Hamburg’s decision to complete her term as Commissioner of the U.S. Food and Drug Administration (FDA), the Multiple Myeloma Research Foundation (MMRF) issued the following statement to recognize the FDA’s significant accomplishments, and Dr. Hamburg’s outstanding partnership on behalf of patients, during her tenure:
“The Multiple Myeloma Research Foundation applauds the exceptional work that Dr. Margaret Hamburg has done to advance the availability of new life-extending and life-saving therapies for people with cancer during her tenure as Commissioner of the U.S. Food and Drug Administration,” said Kathy Giusti, Founder and Executive Chairwoman of the MMRF. “Dr. Hamburg has been a true partner to the multiple myeloma community, and to the entire cancer community, in pursuit of a cure. Her efforts to accelerate the regulatory process have helped deliver two new product approvals* for multiple myeloma in the past three years.”
“FDA’s establishment of the breakthrough therapy designation, among other important innovations under her leadership, will have a lasting impact on multiple myeloma and other diseases. Two breakthrough therapies are currently under development for multiple myeloma, ** and numerous others are in development for other cancers. The future for patients is brighter than ever, thanks in large measure to Dr. Hamburg’s tireless efforts.”
About Multiple Myeloma (MM)
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 24,050 adults (13,500 men and 10,550 women) in the United States will be diagnosed with MM in 2014 and an estimated 11,090 people are predicted to die from the disease. The five-year survival rate for MM is approximately 43%, versus 28% in 1998.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised $275 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency.
* Carfilzomib was approved by the FDA in 2013; pomalidomide was approved in 2013
**Elotuzumab and daratumumab received breakthrough designation in 2014 and 2013, respectively
